SiamakDaneshmandMD

Urology • Los Angeles, CA

Minimally Invasive Surgery, Surgical Oncology

Professor of Urology (Clinical Scholar); Director of Urologic Oncology

Join to view full profile

Dr. Daneshmand is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Daneshmand's full profile

Already have an account?

Office
1516 San Pablo St
Fl 5
Los Angeles, CA 90033
Phone+1 323-865-3700

Fax+1 323-865-0120

Summary

BIOGRAPHY
Dr. Sia Daneshmand is Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as director of urologic oncology, as well as the urologic oncology (SUO) fellowship director at the University of Southern California in Los Angeles. His main clinical interests include bladder, testicular, and advanced kidney cancers. He is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer and is one of the highest volume surgeons for this disease in the country. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy and post-chemo RPLND, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the AUA Guidelines panel for non-muscle invasive bladder cancer, as well as the AUA Guidelines panel for Testicular cancer. He currently serves as the chair of bladder section of the SUO Clinical Trials Consortium (SUO-CTC), is on the scientific steering committee of several bladder cancer clinical trials and has led over a dozen clinical trials in bladder cancer and a pivotal investigator initiated mutli-institutional trial in testicular cancer (SEMS). He is current secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 13 consecutive years. He has been a career leader in academic investigations in bladder and germ cell cancers and was recently appointed as the chair of the SWOG local bladder committee. He has been a visiting professor at 26 institutions worldwide. He has presented over 500 abstracts authored or co-authored over 400 peer-reviewed articles, reviews, and book chapters.

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Urologic Surgical Oncology, 2002 - 2004
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Urology, 1996 - 2002
University of California, Davis, School of MedicineClass of 1996
University of California, Los AngelesB.S., Microbiology & Molecular Genetics, Magna Cum Laude, 1988 - 1992

Certifications & Licensure

OR State Medical License 2004 - Present
CA State Medical License 1997 - 2025
American Board of Urology Urology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2017
America's Top Doctors for Cancer Castle Connolly, 2009-2017
Winner Best Poster of Session AUA, 2016
Faculty Teaching Award USC, 2015
Awarded First Place in the Joseph B. McCarthy Physician Essay Contest AUA, Western Section, 2014
Awarded Overall Best Abstract, First Place AUA, Western Section, 2014
Best Reviewer Award Journal of Urology, 2014-2015
Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Clinical Scholar USC/ Norris Comprehensive Cancer Center, 2011
America’s Top Surgeons 2011
Super Doctors, Los Angeles 2011
Faculty Teaching Award OHSU, 2010
America’s Top Cancer Doctors 2009
America’s Top Doctors 2009
Portland’s Monthly Top Doctors 2007, 2010
Winner, Hadley Award AUA, Western Section, 2005
1st Place- Best of Poster Session AUA, Western Section, 2004
Honorary Director of Urology Nanjing University of Medical Sciences
True Experts List Testis Cancer Resource Center
Departmental Honors University of California, Los Angeles
AOA Honor Medical Society
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Start of enrollment: 2004 Nov 01
Completed
Phase 2
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin Start of enrollment: 2006 Nov 01
Completed
Phase 2
A Comparison of the Studer Pouch Versus the T-Pouch Orthotopic Neobladder Urinary Diversion in Bladder Cancer Patients Start of enrollment: 2002 Jan 04
Completed
Not Applicable
S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer Start of enrollment: 2011 Nov 25
Active, not recruiting
Not Applicable
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer Start of enrollment: 2013 May 01
Withdrawn
Phase 2
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer Start of enrollment: 2014 Aug 28
Completed
Phase 2
Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer Start of enrollment: 2019 Feb 25
Withdrawn
Phase 3
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma Start of enrollment: 2015 Aug 28
Active, not recruiting
Not Applicable
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer Start of enrollment: 2016 May 31
Completed
Phase 1
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations Start of enrollment: 2020 Mar 11
Terminated
Phase 3
A Study of miRNA 371 in Patients With Germ Cell Tumors Start of enrollment: 2020 Jul 28
Recruiting
MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial Start of enrollment: 2023 Jun 08
Recruiting
Blue Light Cystoscopy With Cysview® Registry Start of enrollment: 2014 Apr 01
Recruiting
Intravesical BCG vs GEMDOCE in NMIBC Start of enrollment: 2023 Feb 07
Recruiting
Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Start of enrollment: 2018 Sep 24
Recruiting
Phase 3
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Start of enrollment: 2017 May 12
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Eleven-Year Experience With Midline Extraperitoneal Retroperitoneal Lymph Node Dissection for Germ Cell Tumors.
Muhannad Alsyouf, Alireza Ghoreifi, Arman Ashrafi, Seyedeh-Sanam Ladi-Seyedian, Hamed Ahmadi
The Journal of Urology. 2025-01-01
Residual cancer at radical cystectomy with or without neoadjuvant chemotherapy: a pathological stage-matched comparison.
Leilei Xia, J Everett Knudsen, Daniel S Roberson, Erika L Wood, Anosh Dadabhoy
BJU International. 2025-01-01
Technical Considerations to Minimize False-Positive Findings in Blue Light Cystoscopy for Nonmuscle-Invasive Bladder Cancer.
Alireza Ghoreifi, Siamak Daneshmand
The Journal of Urology. 2025-01-01

Journal Articles

Frailty as a Predictor of Complications After Radical Cystectomy: A Prospective Study of Various Preoperative Assessments
Madeleine L Burg, Anne K Schuckman, Hooman Djaladat, Siamak Daneshmand, Urologic Oncology
Urology Photo Quiz: Adrenal myelolipoma
Quek ML and Daneshmand S, Resident & Staff Physician, 1/1/2004
Placental pathology casebook Complete hydatidiform mole with coexistent term twin pregnancy
Albers E, Daneshmand S, Hull A, J Perinatol, 1/1/2001

Books/Book Chapters

Upper Tract Urothelial Carcinoma
Chapter: The Role of Lymphadenectomy in the Management of Urothelial Carcinoma of the Upper Urinary Tract
Kondo T, Bochner B, Daneshmand S, Zlotta ARSpringer2015
Mastery of Surgery.
Chapter: Radical Cystectomy and Orthotopic Reconstruction for Bladder Cancer.
Skinner E, Daneshmand SLippincott, Williams and WilkinsEdition 6th,2012
Cancer Medicine
Chapter: Neoplasms of the Testis.
Kollmannsberger C, Moore C , Daneshmand S, Hayes-Lattin B, Hansen E, Corless C, Nichols CEdition 8th,2011
Recent Research Developments in Cancer, Vol. 6, Part II.
Chapter: Neuroendocrine differentiation in prostate cancer.
Daneshmand S, Quek ML, and Pinski, J2004
Germ Cell Tumors
Chapter: Radical Orchiectomy.
Daneshmand S, Skinner ECEditors: D. Raghavan.BC Decker2003
Campbell-Walsh Urology
Chapter: Chapter 99: Orthotopic Ileal Neobladder
Skinner EC, Daneshmand SEdition 11th,
Join now to see all

Abstracts/Posters

Preoperative testosterone levels are associated with testicular germ cell tumor histology.
Cory Hugen, Anne Schuckman, Hooman Djaladat, Victoria Cortessis, Siamak Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
Female cystectomy with orthotopic urinary diversion - is fear of urethral recurrence justified?
Cory Hugen, Gus Miranda, Jie Cai, Anne Schuckman, Hooman Djaladat, Sia Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
Enhanced Recovery After Surgery (ERAS) following Radical Cystectomy and Urinary Diversion.
Siamak Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
Advanced in Bladder cancer Management. 'TED Style lecture.'
Siamak Daneshmand, M.D., Society of International Urology, Buenos Aires, Argentina, 1/1/2016
Gastrointestinal Complications Following Radical Cystectomy Using Enhanced Recovery After Surgery (ERAS) Protocol.
Siamak Daneshmand, Soroush T. Bazargani, Hamed Ahmadi, Gus Miranda, Jie Cai, Anne K. Schuckman, and Hooman Djaladat, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
Precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and its effect on oncological outcomes in urothelial bladder cancer.
Soroush T. Bazargani, Thomas Clifford, Hooman Djaladat, Anne Schuckman, David Quinn, Tanya Dorff, Sarmad Sadeghi, Siamak Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
Blight cystoscopy for diagnosis of urothelial bladder cancer: results from a prospective multicenter registry.
Soroush T. Bazargani, Thomas G. Clifford, Hooman Djaladat, MS, Anne K. Schuckman, Brian Willard, Badrinath Konety, Siamak Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
Restrictive Use of Transfusion is Safe in Radical Cystectomy.
Sumeet Syan-Bhanvadia, Siri Drangsholt, Swar Shah, Jie Cai, Gus Miranda, Siamak Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
A Midline Extraperitoneal RPLND Minimizes Perioperative Morbidity.
Sumeet Syan-Bhanvadia, Soroush Bazargani, Thomas Clifford, Jie Cai, Gus Miranda, Siamak Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
Frailty as a Predictor of Complications in Older Patients Undergoing Radical Cystectomy.
Thomas G. Clifford, Soroush T. Bazargani, Jie Cai, Anne K. Schuckman, Hooman Djaladat, Siamak Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
Factors Affecting Continence after Radical Cystectomy and Orthotopic Neobladder.
Thomas G. Clifford, Soroush T. Bazargani, Jie Cai, Kevin Wayne, Anne K. Schuckman, Hooman Djaladat, Siamak Daneshmand, Society of International Urology, Buenos Aires, Argentina, 1/1/2016
Pattern of Random Urine Culture Results 10 Days Post Open Radical Cystectomy.
Kevin Wayne, PA-C, Siamak Daneshmand, Western Section AUA, Kuai, HI, 1/1/2016
Oncological outcomes of concomitant carcinoma in situ of bladder in radical cystectomy patients who underwent neoadjuvant chemotherapy.
Nariman Ahmadi, Cory Hugen, Soroush T Bazargani, Gus Miranda, Siamak Daneshmand, Hooman Djaladat, Western Section AUA, Kuai, HI, 1/1/2016
Factors Associated with Testicular Prostheses Availability and Implantation.
Saum Ghodoussipour, MD, Jeffrey Loh-Doyle, MD, Siamak Daneshmand, Western Section AUA, Kuai, HI, 1/1/2016
Is Pathologic Downstaging at Radical Cystectomy for Clinically Organ Confined Bladder Cancer Associated with A Better Outcome?
Soroush T Bazargani, Nariman Ahmadi, Daniel Furlong, Jie Cai, Gus Miranda, Siamak Daneshmand., Hooman Djaladat, Western Section AUA, Kuai, HI, 1/1/2016
Prior BCG Therapy in Blue Light Cystoscopy for Diagnosis of Urothelial Bladder Cancer.
Soroush T. Bazargani M.D., Thomas Clifford, Hooman Djaladat M.D., M.S., Anne K. Schuckman M.D., Brian Willard MD, Badrinath Konety MD, MBA Siamak Daneshmand, Western Section AUA, Kuai, HI, 1/1/2016
The Association of Intraoperative Fluid Intake and Postoperative Complications in Patients Undergoing Radical Cystectomy with Enhanced Recovery Protocol.
Soroush T. Bazargani MD*, Saum Ghodossipour, MD, Beverly Tse, Gus Miranda BS, Jie Cai MS, Siamak Daneshmand MD, Hooman Djaladat, Western Section AUA, Kuai, HI, 1/1/2016
Prospective Evaluation of Continence after Pelvic Floor Physical Therapy Following Open Radical Cystectomy and Orthotopic Urinary Diversion.
Soroush T. Bazargani, M.D., Thomas Clifford, B.A., Eileen Johnson, PT, DPT, WCS, Kevin Wayne, PA-C, Jie Cai, MS, Gus Miranda, M.S., Hooman Djaladat, M.D., M.S., Anne S..., Western Section AUA, Kuai, HI, 1/1/2016
Factors affecting Gastrointestinal Complications Following Radical Cystectomy Using Enhanced Recovery Protocol.
Soroush T. Bazargani, MD, Gus Miranda, BS, Jie Cai, MS , Anne K. Schuckman, MD, Hooman Djaladat, MD, MS and Siamak Daneshmand, Western Section AUA, Kuai, HI, 1/1/2016
Effect of precystectomy epithelial tumor marker response to neoadjuvant chemotherapy on oncological outcomes in urothelial bladder cancer.
Soroush T. Bazargani, Thomas Clifford, Hooman Djaladat, Anne Schuckman, David Quinn, Tanya Dorff, Sarmad Sadeghi, Siamak Daneshmand, Western Section AUA, Kuai, HI, 1/1/2016
Midline Extraperitoneal Approach to RPLND.
Sumeet Syan, Siamak Daneshmand, Western Section AUA, Kuai, HI, 1/1/2016
Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Germ Cell Tumor: Minimizing Surgical Morbidity.
Sumeet Syan-Bhanvadia M.D., Soroush T. Bazargani M.D., Thomas G. Clifford MS4., Jie Cai M.S., Gus Miranda, Siamak Daneshmand, Western Section AUA, Kuai, HI, 1/1/2016
Restrictive Transfusion in Open Radical Cystectomy is Safe.
Sumeet Syan-Bhanvadia*, M.D., Siri Drangsholt, M.D., Swar Shah M.S., Jie Cai, Gus Miranda, Siamak Daneshmand, M.D., Western Section AUA, Kuai, HI, 1/1/2016
Urinary tract infections following radical cystectomy and urinary diversion.
Thomas G. Clifford, Behrod Katebian, Soroush T. Bazargani, Jie Cai, Gus Miranda, Siamak Daneshmand, Hooman Djaladat, Western Section AUA, Kuai, HI, 1/1/2016
Bowel Culture and Postoperative Infectious Complications Following Radical Cystectomy and Urinary Diversion.
Thomas G. Clifford, Hana Yokoi, Soroush T. Bazargani, MD, Gus Miranda, Anne K. Schuckman, MD, Siamak Daneshmand, MD, Hooman Djaladat, Western Section AUA, Kuai, HI, 1/1/2016
Join now to see all

Lectures

Urinary Diversion Following Radical Cystectomy- Separating Myth from Fact
1/1/2016
AUA Difficult Cases Plenary II Testis Cancer.
1/1/2016
AUA Bladder Cancer Guidelines Update
1/1/2016
Management of Early Stage Testicular Cancer
1/1/2016
High Grade T1 Bladder Cancer- BCG or Cystectomy?
1/1/2016
Advances in Detection of Non-Muscle invasive Bladder Cancer.
1/1/2016
Urinary Diversion, Bladder Cancer, Upper Tract Urothelial cancer
Mclean, VA - 1/1/2016
Evaluation of Gastrointestinal Complications Following Radical Cystectomy Using Enhanced Recovery Protocol
Washington, DC - 1/1/2016
4 day hospital stay following radical cystectomy. Is it feasible in Europe?
Lisbon, Portugal - 1/1/2016
Blue light Cystoscopy in the Diagnosis of Bladder Cancer
Las Vegas, NV - 1/1/2015
Enhanced Recovery Protocol Following Radical Cystectomy.
Ohio State University, Columbus, OH - 1/1/2015
Photodynamic diagnosis of non-muscle invasive bladder cancer.
Mt. Sinai Icahn School of Medicine, New York, NY - 1/1/2015
Shelby Webster Testis cancer conference: Case Studies.
Virginia Mason, Seattle, WA - 1/1/2015
Serum tumor markers in bladder cancer- is there a role?
Athens, Greece - 1/1/2015
ERAS- Does it level the playing field?
Bethesda, MD - 1/1/2015
Cystectomy for High Grade T1 Bladder cancer- Debate
Charlotte, NC - 1/1/2015
Patient Navigation through Therapy.
Charlotte, NC - 1/1/2015
Management of complex germ cell tumors.
San Diego, CA - 1/1/2014
Enhanced Recovery After Surgery (ERAS) following radical cystectomy for bladder cancer.
University of California, Davis - 1/1/2014
Management of High Grade T1 Urothelial Carcinoma
Tehran University of Medical Sciences, Tehran, Iran - 1/1/2014
Minimizing Morbidity of RPLND.
Bethesda, MD - 1/1/2014
What a Urologist Should Do Based Upon Long Term Side Effects of Chemotherapy.
Bethesda, MD - 1/1/2014
Determining the role of cystectomy for High Grade T1 Urothelial Carcinoma
Kish Island, Iran - 1/1/2014
Bladder sparing strategies.
Los Angeles, CA - 1/1/2014
Management of Stage I non-seminomatous germ cell tumor
San Diego, CA - 1/1/2014
Join now to see all

Other

Lymph node dissection in bladder cancer. (Performed radical cystectomy for bladder cancer.)
Daneshmand S, Labbafinejad Urology Department
Shahid Beheshti University of Medical Sciences, Tehran, Iran - 1/1/2014
Health Heroes- Blue light cystoscopy
Daneshmand S, Discovery Health
1/1/2013
Treatment for Testicular cancer.
Daneshmand S, Doctors TV show
http://www.thedoctorstv.com/videolib/init/8028
1/1/2012
Modern Management of Testis Cancer.
Daneshmand S, Visiting Professor and Surgeon
Tacoma, WA - 1/1/2011
Radical Cystectomy and orthotopic ileal neobladder and augmentation enterocystoplasty (2 cases) in Nanjing, China.
Daneshmand S, Urologists at Urology updates Meeting
Nanjing, China - 1/1/2010
Urinary diversion following radical cystectomy. Contemporary Management of Vena Caval tumor thrombus.
Daneshmand S, Live Broadcast
Peking First University of Medical Sciences, Beijing, China - 1/1/2010
Surgical Management of Testis Cancer.
Daneshmand S, Testis Cancer Conference
Warsaw, Poland - 1/1/2006
Neobladder made from patients' own intestine.
Daneshmand S, Ivanhoe Broadcasting, News Health Segment
1/1/2006
Advanced Prostate Cancer: AUA 2006 Update. CME article.
Daneshmand S, Medscape Reviews
1/1/2006
Bladder Cancer- Potentially Curable With The Right Diagnosis And Treatment
Daneshmand S, Annual Report
OHSU Cancer Institute - 1/1/2005
Advanced Prostate Cancer: AUA 2005 Update. CME article.
Daneshmand S, Medscape Reviews
1/1/2005
OHSU Expands Options for Bladder Cancer Patients.
Daneshmand S, OHSU Consult News Notes
1/1/2004
Positive margins predict late TCC recurrence: lymph node involvement, multifocality, extravesical extension also strong predictors.
Daneshmand S, Urology Times
1/1/2004
Bladder Cancer Diagnosis and Treatment- Interview.
Daneshmand S, KSCI
Los Angeles, CA - 1/1/2003
Prognosis of Patients with Stage D1 Prostate Cancer.
Daneshmand S, Stein JP, Lieskovsky G, Skinner E, and Skinner DG, AUA News
1/1/2003
TCC in seminal vesicles, T4b tumors have same prognosis: seminal vesicle involvement is worse than prostate stromal involvement.
Daneshmand S, Urology Times
1/1/2003
Epidemiology and etiology of urothelial bladder cancer.
Daneshmand S, Becker T, UpToDate
Muscle invasive bladder cancer.
Daneshmand S, AUA Core Curriculum
Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder
Daneshmand S, Becker TM
http://www.uptodate.com/contents/epidemiology-and-etiology-of-urothelial-transitional-cell-carcinoma
UpToDate, Wolters Kluwer Health - 2013-01-30
Bladder Cancer- Modern Healing shown on Portland prime time TV.
Daneshmand S
http://modernhealing.tv/portland2.html
Join now to see all

Authored Content

Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018

Press Mentions

High Response Rate for TAR-200 plus Cetrelimab in BCG-Unresponsive NMIBCMay 24th, 2023
Novel Chemotherapy Delivery System May Fill Key Gap in Bladder Cancer TreatmentMay 3rd, 2023
Novel Chemo Delivery System Achieves High Response Rate in Bladder CancerMay 2nd, 2023
Join now to see all